Navigation Links
Sinovac Appoints Kenneth Lee to Board of Directors
Date:5/31/2011

BEIJING, May 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the appointment of Mr. Kenneth Lee as a director to the Board of the Company effective on May 31, 2011 to replace Mr. Xianping Wang who resigned from the Board due to personal reasons.

Kenneth Lee is a Principal at SAIF Partners, a leading growth capital fund focused on China and India.  He brings more than 15 years of experience across private equity investment, corporate finance, and business development in China to Sinovac.  Before becoming a member of the SAIF team in 2007, Mr. Lee previously was with Topsec Holdings, RimAsia Capital Partners, Delta Associates – the exclusive advisor to Asia Equity Infrastructure Fund, CNK Telecom, H&Q Asia Pacific, and Salomon Brothers in New York.  Mr. Lee is a graduate of Amherst College.

Dr. Weidong Yin, Chairman and CEO said: "We are pleased to invite Kenneth Lee to our Board. Given his wealth of experience in corporate finance and business development in China, I believe he will bring new perspectives and insights to our Board in the interest of the Company and shareholders. I look forward to the contributions he will make to our Company."

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received the orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris LeeSinovac Biotech Ltd.Tel:  +86-10-8279-9871/9659Fax:  +86-10-6296-6910Email: ir@sinovac.comInvestors:Stephanie Carrington/Amy GlynnThe Ruth GroupTel:  +1-646-536-7017/7023Email: scarrington@theruthgroup.comaglynn@theruthgroup.comMediaJason RandoThe Ruth GroupTel:  +1-646-536-7025Email:  jrando@theruthgroup.com
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
2. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
3. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
4. Sinovac Announces Plan to Launch Offering of Common Shares
5. Sinovac Announces Recent Developments
6. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
7. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
8. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
9. Sinovac Files Shelf Registration Statement
10. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
11. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016   Mallinckrodt Pharmaceuticals (NYSE: ... announced that it received a perfect score of 100 ... national benchmarking survey and report on corporate policies and ... workplace equality, administered by the Human Rights Campaign (HRC) ... businesses which also earned top marks this year. ...
(Date:12/5/2016)... Dec. 5, 2016 ... antibiotics have emerged as a crucial class of ... In addition, antibiotics are also used for prophylactic ... immunocompromised patients (cancer patients undergoing chemotherapy). However, the ... food production, has rapidly accelerated an evolutionary response ...
(Date:12/5/2016)... 5, 2016 Special purpose needles are used in ... fluid and cells from organs or lumps and are available ... The global market for special purpose needles is showing a ... of revenue, the global special purpose needles market is projected ... period (2016–2026) and is expected to be valued at US$ ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... Public middle and high ... to apply for a 2016/2017 California Casualty Thomas R. Brown Athletics Grant. The ... can receive up to $3,000. , The grant is named after California ...
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... thrilled to formally announce its Not a Moment to Lose fundraising campaign. As ... rally supporters dedicated to declaring victory over cancer. The campaign aims to raise ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... is now offering HIAC particle counting and sizing services for USP 788 and ... instituted the new service as a response to the needs of pharmaceutical and ...
(Date:12/6/2016)... ... 2016 , ... METTLER TOLEDO has launched its online ... papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user manuals, ... webinars and videos available online, visit the METTLER TOLEDO Expertise Library . ...
Breaking Medicine News(10 mins):